Tekmira Pharmaceuticals this week announced that Spectrum Pharmaceuticals, which licensed Tekmira's non-RNAi cancer drug Marqibo earlier this year, has launched the product in the US.
The drug is a version of the approved chemotherapeutic vincristine formulated with Tekmira's liposome technology. It is a legacy product developed by Tekmira prior to its becoming a pure-play RNAi drug developer, and was later licensed to Talon Therapeutics. Talon was acquired by Spectrum in July.
Tekmira stands to receive royalties on sales of Marqibo.